Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

Is Recursion Pharmaceuticals a Meme Stock?

Is that the case? Let's look into it and decide whether the company is worth investing in.

Is Recursion Pharmaceuticals Inc. (RXRX) One of the Best Mid Cap Stocks to Buy According to Hedge Funds?

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best mid cap stocks to buy according to hedge funds.
TipRanks on MSN

Recursion Pharmaceuticals Registers Resale of 7 Million Shares

The latest announcement is out from Recursion Pharmaceuticals ( ($RXRX) ). On November 26, 2025, Recursion Pharmaceuticals filed a prospectus ...
AOL

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...
The Globe and Mail

Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...
Nasdaq

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is slated to report third-quarter 2025 results on Nov. 5, before the opening bell.